F-1/A: Pheton Holdings Ltd Files Amendment No. 4 to Form F-1 for Proposed IPO

Pheton Holdings Ltd files an amendment to its Form F-1 registration statement for its initial public offering of Class A ordinary shares.

Summary

• Pheton Holdings Ltd, a Cayman Islands holding company, has filed Amendment No. 4 to its Form F-1 registration statement.
• The company is planning an initial public offering (IPO) of 2,500,000 Class A ordinary shares.
• The expected IPO price is between $4.00 and $5.00 per share.
• Existing shareholders may offer an additional 1,250,000 Class A ordinary shares (Resale Shares) after the IPO.
• Pheton Holdings Ltd will not receive any proceeds from the sale of Resale Shares.
• The company has applied to list its Class A ordinary shares on the Nasdaq Capital Market under the symbol PTHL.
• The closing of the offering is conditioned upon Nasdaq's final approval of the listing application.
• The company operates its business through its subsidiaries, with all operations conducted by Beijing Feitian Zhaoye Technology Co., Ltd. in China.
• The company's structure is not a VIE, but changes in PRC laws could adversely affect operations and the value of Class A ordinary shares.
• The company completed filing procedures with the CSRC on December 8, 2023, and the completion was posted on the official website of the CSRC on December 11, 2023.
• The company intends to use approximately 30% of the net proceeds for research and development, technology upgrade; approximately 30% for market expansion; approximately 20% for improve internal control and operation system; and approximately 20% for supplement liquidity.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The company is pursuing an IPO and has completed filing procedures with the CSRC, which are positive steps. However, there are risks associated with PRC laws and regulations, and the company's revenue and gross profit decreased for the six months ended June 30, 2023.

Positives

• The company has completed filing procedures with the CSRC, a requirement for offering Class A ordinary shares to foreign investors.
• The company intends to use approximately 30% of the net proceeds for research and development, technology upgrade; approximately 30% for market expansion; approximately 20% for improve internal control and operation system; and approximately 20% for supplement liquidity.

Negatives

• Changes in PRC laws and regulations could adversely affect the company's operations and the value of its Class A ordinary shares.
• The company may be subject to investigations by competent regulators, fines or penalties, ordered to suspend its relevant operations and rectify any non-compliance, prohibited from engaging in relevant business or conducting any offering, and these risks could result in a material adverse change in our operations, limit our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.

Risks

• The company's structure is not a VIE, but changes in PRC laws could adversely affect operations and the value of Class A ordinary shares.
• The company may be subject to cybersecurity review, and failure to comply with related laws and regulations may result in fines or other penalties.
• The company may be required to perform additional procedures in connection with the provision of accounting archives under the Confidentiality and Archives Administration Provisions.
• The company may be subject to investigations by competent regulators, fines or penalties, ordered to suspend its relevant operations and rectify any non-compliance, prohibited from engaging in relevant business or conducting any offering, and these risks could result in a material adverse change in our operations, limit our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value or become worthless.
• If the PCAOB is unable to inspect the company's auditors, trading of Class A ordinary shares may be prohibited by the SEC.

Future Outlook

The company expects its operational and financial performance to gradually improve and stabilize in the second half of 2023.

Industry Context

The document mentions the increasing cancer burden in China and globally, highlighting the need for effective treatment strategies, including radiotherapy. It also discusses the growth of the radiotherapy oncology market in China and the increasing acceptance of radiotherapy as a cancer treatment.

Comparison to Industry Standards

• The document mentions that WHO stipulates that the standard of radiotherapy equipment is 2-4 units per million people, and in developed countries and regions, radiotherapy equipment can even reach 6-12 units per million people.
• The document states that in 2021, China had 1.63 units of radiotherapy equipment per million people, indicating a need for further development in the radiotherapy market.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company's operations are adversely affected by changes in PRC laws and regulations.
• Shareholders may face difficulties in protecting their interests due to the company's incorporation under Cayman Islands law.

Next Steps

• The company needs to obtain Nasdaq's final approval for the listing application.
• The company intends to use the net proceeds from the IPO for research and development, market expansion, improvements to internal control and operation system, and supplemental liquidity.

Key Dates

Keywords

IPO, Class A ordinary shares, Pheton Holdings Ltd, CSRC, Nasdaq, China, Overseas Listing Trial Measures, PCAOB, HFCA Act, brachytherapy TPS